Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
This article was originally published in The Tan Sheet
Executive Summary
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
You may also be interested in...
Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27
Bayer Attributes Recent Aleve Bounce To Advisory Panel Discussions
Bayer credits a rebound in Aleve sales in March to favorable FDA advisory committee discussions on the safety of naproxen
Naproxen May Be “Exception” To NSAID Rule, But Data Is Lacking – FDA
An FDA memorandum released April 15 points to naproxen as a potentially safer NSAID compared to other drugs in the class